Register      Login
Sexual Health Sexual Health Society
Publishing on sexual health from the widest perspective
Shopping Cart: ( empty )
You are here: Home > Journals > SH > SH09131
EDITORIAL
Contents Vol 7(3)

For debate: that Australia should consider changing to the bivalent vaccine

Peter L. Stern
+ Author Affiliations
- Author Affiliations

CR UK Immunology Group, Paterson Institute for Cancer Research, University of Manchester, Manchester M20 4BX, UK. Email: pstern@picr.man.ac.uk

Sexual Health 7(3) 238-241 https://doi.org/10.1071/SH09131
Submitted: 1 December 2009  Accepted: 28 January 2010   Published: 19 August 2010


References


[1] Cervarix®. Summary of Product Characteristics. Uxbridge: GSK; 2009. Available online at: http://emc.medicines.org.uk/medicine/20204/SPC/Cervarix/#PRODUCTINFO [verified February 2010].

[2] Gardasil®. Summary of Product Characteristics. Whitehouse Station: Merck; 2009. Available online at: http://www.gardasil.com/ [verified February 2010] .

[3] Stanley M,  Lowy DR,  Frazer I. Chapter 12: prophylactic HPV vaccines: underlying mechanisms. Vaccine 2006; 24(Suppl 3): S106–113.
| Crossref | GoogleScholarGoogle Scholar | [verified February 2010].

[8] Villa LL,  Costa RL,  Petta CA,  Andrade RP,  Paavonen J,  Iversen OE, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 2006; 95 1459–66.
| Crossref | GoogleScholarGoogle Scholar | PubMed | [accessed 11 February 2010].

[26] Australian of the Year 2006, National Australia Day Council, Old Parliament House, King George Terrace, Parkes ACT 2600, Australia. Available online at: http://www.australianoftheyear.org.au/pages/page58.asp [verified February 2010].

[27] Roughead EE,  Gilbert AL,  Vitry AI. The Australian funding debate on quadrivalent HPV vaccine: a case study for the national pharmaceutical policy. Health Policy 2008; 88 250–7.
| Crossref | GoogleScholarGoogle Scholar | PubMed | [verified May 2009].